The program’s spending on the therapy has quintupled since 2021, far outstripping the growth in diagnoses and raising concerns about overprescribing and fraud.
The program’s spending on the therapy has quintupled since 2021, far outstripping the growth in diagnoses and raising concerns about overprescribing and fraud.
